A 7 1 9 -A 8 1 3 A743 were based on the 2013 utilisation volume data. Other local specific considerations e.g. subsidized selling prices and co-payments were included in the analyses for an assumed size of eligible patients. Sensitivity analyses were conducted. Results: The adoption rates of BIAsp were assumed to increase from 23.6% in 2013 to 30% or 36.5% in 2018 for base case and upside scenario, respectively. In comparison to base case scenario, increases in adoption rate of BIAsp were associated with a cumulative increase up to slightly greater than S$ 2.02M in insulin acquisition cost but a potential cumulative net saving up to approximately S$0.92M in overall total costs over 5 years, attributing to subsidized selling price of BIAsp assuming it is included standard drug list and its significantly lower major hypoglycaemia risk, respectively. Cost savings were predicted for other complications. ConClusions: The wider adoption of BIAsp was predicted to result in net cost savings from patient perspective in Singapore. More cost saving would be estimated in analyses with reduced productivity loss from a societal perspective.

A 7 1 9 -A 8 1 3 A745 fees, and costs for diagostic procedures, hospitalization, treatment costs for adverse drug reactions (ADRs) and other costs arising from medical intervention among the sole surgical treatment group (35 cases), the group of preoperative treatment with lanreotide (36 cases), and the group of preoperative treatment with octreotide (18 cases). Results: Based on the good compatibility of tumor size, postoperative average length of stay in hospital, biochemical indicators (IGF-I, GH ) among the three groups, there was no statistical difference in the clinical effectiveness (x 2 = 2.81, P = 0.250). As to the total medical costs per case, both octreotide group and lanreotide group were higher than the sole operation group with a statistical significant (F = 21.05, P = 0.000), and the lanreotide group (70521 ± 25677 Yuan) was lower than the octreotide group (80283 ± 21486 Yuan) with the Median non-parametric test (P = 0.037). The sensitivity analysis showed that the cost advantage of lanreotide relected in prolonging the length of the preoperative treatment. ConClusions: According to the data of direct medical costs from the sampling hospital in Shanghai, lanreotide has more cost advantage comparing with octreotide.objeCtives: Metformin is the first-line oral hypoglycemic agent for type 2 diabetes mellitus (T2DM) per international guideline with proven efficacy, safety and cost-effectiveness. However, little information exists comparing it with acarbose. This study aims to ascertain both the effectiveness and cost-effectiveness of these two extensively-adopted agents in treatment of T2DM. Methods: Randomised Controlled Trials comparing metformin and acarbose with placebo and sulfonylureas were systematically reviewed from Chinese (CNKI) and English (PubMed) literatures. Meta-analysis and Bucher-method-based indirect comparisons were conducted to compare the hypoglycemic-effects of metformin and acarbose directly and indirectly by using common comparators. The weighted-mean-difference and 95%CIs were calculated. Cost-minimization analysis was performed from the perspective of medical insurance. Common clinical scenarios were set according to clinical practices and physicians' prescribing behaviors in China, which could mirror real-life cost data. Results: The direct comparison (8 trials) indicated treatment difference between metformin and acarbose for reduction of HbA1c was -0.06% (95% CI, -0.32 to 0.20). In the indirect comparisons (67 trials), using placebo and sulphonylureas as common comparators, metformin achieved significant HbA1c reduction than acarbose, by -0.38% (95% CI, -0.736 to -0.024) and -0.34% (95% CI, -0.651 to -0.029) respectively. Cost-minimization analysis was conducted on the assumption that these two agents had same hypoglycemic effects. In the first two scenarios, acarbose was assumed to titrate from 50mg/day up to 150 mg/day (weight< 60kg) or 300mg/ day (weight> = 60kg) as usual max-dose, and the annual-costs were ¥2,656.36 and ¥5,208.84. In the last two scenarios, metformin w...